

Silco Pharmaceuticals Limited
Statement of Financial Position
As at December 31, 2018

Particulars	Amount in Taka	
	31 Dec. 2018	30 June 2018
Assets		
Non Current Assets	1,228,412,521	1,249,517,443
Property, Plant & Equipment	1,164,212,228	1,175,166,949
Capital Work in Progress	64,200,293	74,350,494
Current Assets	995,080,842	896,796,670
Inventories	413,650,696	398,357,928
Trade Receivables	468,731,528	389,362,515
Advance, Deposits and Prepayments	101,258,631	93,413,781
Cash and Cash Equivalents	11,439,987	15,662,446
Total Assets	2,223,493,364	2,146,314,114
Shareholders Equity and Liabilities		
Shareholders Equity	1,789,236,722	1,741,076,872
Share Capital	643,700,000	643,700,000
Retained Earnings	1,145,536,722	1,097,376,872
Non-Current Liabilities	201,512,454	196,477,075
Deferred Tax Liability	201,512,454	196,477,075
Current Liabilities	232,744,187	208,760,168
Trade Payable	17,077,299	16,328,305
Creditors & Accruals	10,554,421	11,920,846
Liability for WPPF	11,809,544	8,104,940
Current Tax Liability	193,302,923	172,406,076
Total Shareholders Equity and Liabilities	2,223,493,364	2,146,314,114
Net Asset Value (NAV) per Share	27.80	27.05

The annexed notes form an integral part of these financial statements.

sd/-	sd/-	sd/-	sd/-
Chief Financial Officer	Company Secretary	Managing Director	Chairman

Dated: January 27, 2019
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Profit or Loss and other Comprehensive Income
For the period ended December 31, 2018

Particulars	Amount in Taka		Quarterly Results	
	01.07.2018 to 31.12.2018	01.07.2017 to 31.12.2017	01.10.2018 to 31.12.2018	01.10.2017 to 31.12.2017
Sales /Revenue	466,818,686	460,822,038	244,317,939	256,653,604
Less: Cost of Goods Sold	325,371,987	320,531,208	171,907,389	178,200,629
Gross Profit	141,446,698	140,290,830	72,410,550	78,452,975
Less: Operating Expenses	63,253,563	61,702,264	31,914,807	31,218,991
Profit from Operation	78,193,135	78,588,566	40,495,743	47,233,984
Less: Financial Expenses	499,709	612,713	261,855	308,087
Add: Non-operation Income	103,255	187,889	54,932	145,864
Profit before Contribution to WPPF	77,796,681	78,163,742	40,288,820	47,071,761
Less: Workers' Profit Participation/Welfare Fund Expenses	3,704,604	3,722,083	1,918,515	2,241,512
Profit before Tax	74,092,077	74,441,659	38,370,305	44,830,249
Less: Income Tax Expenses	25,932,227	26,054,581	13,429,607	15,690,587
Current Tax	20,896,847	20,697,887	5,027,865	7,424,966
Deferred Tax	5,035,379	5,356,693	8,401,742	8,265,621
Net Profit after Tax	48,159,850	48,387,078	24,940,698	29,139,662
Earnings per Share (EPS)	0.75	0.75	0.39	0.45

The annexed notes form an integral part of these financial statements.

sd/-	sd/-	sd/-	sd/-
Chief Financial Officer	Company Secretary	Managing Director	Chairman

Dated: January 27, 2019
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Changes in Equity
For the period ended December 31, 2018

(Amount in Taka)

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2018	643,700,000	1,097,376,872	1,741,076,872
Net Profit during the period	-	48,159,850	48,159,850
Balance as on December 31, 2018	643,700,000	1,145,536,722	1,789,236,722

Statement of Changes in Equity
For the period ended December 31, 2017

(Amount in Taka)

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as at July 01, 2017	643,700,000	992,012,653	1,635,712,653
Net Profit during the period	-	48,387,078	48,387,078
Balance as on December 31, 2017	643,700,000	1,040,399,731	1,684,099,731

sd/- sd/- sd/- sd/-
Chief Financial Officer Company Secretary Managing Director Chairman

Dated: January 27, 2019
Place: Dhaka

Silco Pharmaceuticals Limited
Statement of Cash Flows
For the period ended December 31, 2018

Particulars	Amount in Taka	
	01.01.2018 to 31.12.2018	01.01.2017 to 31.12.2017
A. Cash Flows from Operating Activities		
Cash received from Customers	387,449,673	374,657,469
Cash received from Non-operating income	103,255	187,889
Cash Paid to Suppliers	(287,468,081)	(283,420,177)
Cash Paid to Employees	(50,209,666)	(46,675,171)
Cash Paid to Others	(33,186,680)	(41,420,380)
Income Tax Paid	(456,287)	(410,000)
Net cash flows from operating activities	<u>16,232,214</u>	<u>2,919,630</u>
B. Cash Flows from Investing Activities		
Acquisition of Property, Plant & Equipment	(2,590,753)	(412,375)
Cash Payments for Capital Work-in-Progress	(17,364,210)	(3,723,000)
Net cash flows from investing activities	<u>(19,954,963)</u>	<u>(4,135,375)</u>
C. Cash Flows from Financing Activities		
Net Payment for Financial Expenses	(499,709)	(612,713)
Net Received/(Payment) in Long Term Loan	-	(2,324,462)
Net Cash flows from financing activities	<u>(499,709)</u>	<u>(2,937,175)</u>
D. Net Increase/(Decrease) Cash and Cash Equivalents (A+B+C)	<u>(4,222,458)</u>	<u>(4,152,920)</u>
E. Opening Cash and Cash Equivalents	15,662,446	17,675,005
F. Closing Cash and Cash Equivalents (D+E)	<u>11,439,988</u>	<u>13,522,085</u>
Net Operating Cash Flows Per Share (NOCFPS)	<u>0.25</u>	<u>0.05</u>

sd/-	sd/-	sd/-	sd/-
Chief Financial Officer	Company Secretary	Managing Director	Chairman

Dated: January 27, 2019
Place: Dhaka